Chemical Structure
TDZD-8 [327036-89-5]
AG-CR1-3740
CAS Number327036-89-5
Product group Chemicals
Estimated Purity>98%
Molecular Weight222.3
Overview
- SupplierAdipoGen Life Sciences
- Product NameTDZD-8 [327036-89-5]
- Delivery Days Customer10
- CAS Number327036-89-5
- CertificationResearch Use Only
- Estimated Purity>98%
- Hazard InformationDanger
- Molecular FormulaC10H10N2O2S
- Molecular Weight222.3
- Scientific DescriptionChemical. CAS: 327036-89-5. Formula: C10H10N2O2S. MW: 222.3. TDZD-8 is a non-ATP competitive selective inhibitor of the serine/threonine kinase glycogen synthase kinase 3beta (GSK3beta; IC50 = 2microM), binding to the active site of GSK3beta. It does not significantly affect the activities of Cdk-1/cyclin B, CK-II, cAMP-dependent protein kinase or protein kinase C (IC50s = >100 microM), but inhibits PKC and Flt-3 activities (IC50 = 1.4-5.5microM and 673nM, respectively). TDZD-8 has been used to study the role of GSK3beta during stem cell differentiation as well as in cell and animal models of Alzheimers disease and other neurodegenerative disorders. TDZD-8 is a potent anti-proliferative and pro-apoptotic agent of glioma cells in vitro and in vivo. These effects are associated with an early activation of extracellular signal-regulated kinase (ERK), which is followed by an increased expression of the early growth response-1 (EGR-1) and p21. TDZD-8 potentially inhibits the 33.8-kDa Main protease (Mpro)/3C-like protease of SARS-CoV-2, consequently inhibiting viral transcription and replication and possibly inhibiting spread of COVID-19. - TDZD-8 is a non-ATP competitive selective inhibitor of the serine/threonine kinase glycogen synthase kinase 3beta (GSK3beta; IC50 = 2microM), binding to the active site of GSK3beta. It does not significantly affect the activities of Cdk-1/cyclin B, CK-II, cAMP-dependent protein kinase or protein kinase C (IC50s = >100 microM), but inhibits PKC and Flt-3 activities (IC50 = 1.4-5.5microM and 673nM, respectively). TDZD-8 has been used to study the role of GSK3beta during stem cell differentiation as well as in cell and animal models of Alzheimers disease and other neurodegenerative disorders. TDZD-8 is a potent anti-proliferative and pro-apoptotic agent of glioma cells in vitro and in vivo. These effects are associated with an early activation of extracellular signal-regulated kinase (ERK), which is followed by an increased expression of the early growth response-1 (EGR-1) and p21. TDZD-8 potentially inhibits the 33.8-kDa Main protease (Mpro)/3C-like protease of SARS-CoV-2, consequently inhibiting viral transcription and replication and possibly inhibiting spread of COVID-19.
- SMILESO=C(N1CC2=CC=CC=C2)N(C)SC1=O
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200